New capital round open until february 5, 2024

Value per share of 5,80 until 27/12/2023, 6,50 after

We aim to finance Phase III clinical trials for brain tumor treatment. Last round has been the biggest in Laminar’s history with 9 million euros raised.

For more information about this investment opportunity click here


Company News

Scientific publications